These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 12819531)

  • 21. Atazanavir/ritonavir: a review of its use in HIV therapy.
    von Hentig N
    Drugs Today (Barc); 2008 Feb; 44(2):103-32. PubMed ID: 18389089
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Lopinavir/ritonavir: a review of its use in the management of HIV infection.
    Oldfield V; Plosker GL
    Drugs; 2006; 66(9):1275-99. PubMed ID: 16827606
    [TBL] [Abstract][Full Text] [Related]  

  • 23. GRL-079, a Novel HIV-1 Protease Inhibitor, Is Extremely Potent against Multidrug-Resistant HIV-1 Variants and Has a High Genetic Barrier against the Emergence of Resistant Variants.
    Delino NS; Aoki M; Hayashi H; Hattori SI; Chang SB; Takamatsu Y; Martyr CD; Das D; Ghosh AK; Mitsuya H
    Antimicrob Agents Chemother; 2018 May; 62(5):. PubMed ID: 29463535
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Drug resistance mutations and newly recognized treatment-related substitutions in the HIV-1 protease gene: prevalence and associations with drug exposure and real or virtual phenotypic resistance to protease inhibitors in two clinical cohorts of antiretroviral experienced patients.
    Torti C; Quiros-Roldan E; Monno L; Patroni A; Saracino A; Angarano G; Tinelli C; Lo Caputo S; Tirelli V; Mazzotta F; Carosi G; ;
    J Med Virol; 2004 Sep; 74(1):29-33. PubMed ID: 15258965
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cost effectiveness of lopinavir/ritonavir compared with atazanavir in antiretroviral-naive patients: modelling the combined effects of HIV and heart disease.
    Simpson KN; Luo MP; Chumney EC; King MS; Brun S
    Clin Drug Investig; 2007; 27(1):67-74. PubMed ID: 17177581
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Improving lopinavir genotype algorithm through phenotype correlations: novel mutation patterns and amprenavir cross-resistance.
    Parkin NT; Chappey C; Petropoulos CJ
    AIDS; 2003 May; 17(7):955-61. PubMed ID: 12700444
    [TBL] [Abstract][Full Text] [Related]  

  • 27. HIV protease mutations associated with amprenavir resistance during salvage therapy: importance of I54M.
    Murphy MD; Marousek GI; Chou S
    J Clin Virol; 2004 May; 30(1):62-7. PubMed ID: 15072756
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of ritonavir-boosted darunavir, atazanavir and lopinavir on adipose functions and insulin sensitivity in murine and human adipocytes.
    Capel E; Auclair M; Caron-Debarle M; Capeau J
    Antivir Ther; 2012; 17(3):549-56. PubMed ID: 22293506
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Genotypic and phenotypic evolution of HIV type-1 protease during in vitro sequential or concomitant combination of atazanavir and amprenavir.
    Cunyat F; Ruiz L; Marfil S; Puig T; Bofill M; Blanco J; Clotet B; Cabrera C
    Antivir Ther; 2010; 15(3):431-6. PubMed ID: 20516562
    [TBL] [Abstract][Full Text] [Related]  

  • 30. GS-8374, a novel HIV protease inhibitor, does not alter glucose homeostasis in cultured adipocytes or in a healthy-rodent model system.
    Hruz PW; Yan Q; Tsai L; Koster J; Xu L; Cihlar T; Callebaut C
    Antimicrob Agents Chemother; 2011 Apr; 55(4):1377-82. PubMed ID: 21245443
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In vitro antiviral activity and cross-resistance profile of PL-100, a novel protease inhibitor of human immunodeficiency virus type 1.
    Dandache S; Sévigny G; Yelle J; Stranix BR; Parkin N; Schapiro JM; Wainberg MA; Wu JJ
    Antimicrob Agents Chemother; 2007 Nov; 51(11):4036-43. PubMed ID: 17638694
    [TBL] [Abstract][Full Text] [Related]  

  • 32. HIV protease inhibitors activate the adipocyte renin angiotensin system.
    Boccara F; Auclair M; Cohen A; Lefèvre C; Prot M; Bastard JP; Capeau J; Caron-Debarle M
    Antivir Ther; 2010; 15(3):363-75. PubMed ID: 20516556
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The role of polymorphisms at position 89 in the HIV-1 protease gene in the development of drug resistance to HIV-1 protease inhibitors.
    Martinez-Cajas JL; Wainberg MA; Oliveira M; Asahchop EL; Doualla-Bell F; Lisovsky I; Moisi D; Mendelson E; Grossman Z; Brenner BG
    J Antimicrob Chemother; 2012 Apr; 67(4):988-94. PubMed ID: 22315096
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Resistance to amprenavir before and after treatment with lopinavir/ritonavir in highly protease inhibitor-experienced HIV patients.
    Hasson H; Gianotti N; Danise A; Seminari E; Boeri E; Nozza S; Castagna A; Lazzarin A
    AIDS; 2004 Jan; 18(1):123-7. PubMed ID: 15090838
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Inhibition of HIV-2 protease by HIV-1 protease inhibitors in clinical use.
    Brower ET; Bacha UM; Kawasaki Y; Freire E
    Chem Biol Drug Des; 2008 Apr; 71(4):298-305. PubMed ID: 18312292
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacokinetics of amprenavir given once or twice a day when combined with atazanavir in heavily pre-treated HIV-positive patients.
    Guffanti M; De Pascalis CR; Seminari E; Fusetti G; Gianotti N; Bassetti D; Galli A; Castagna A; Lazzarin A
    AIDS; 2003 Dec; 17(18):2669-71. PubMed ID: 14685066
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Amprenavir or fosamprenavir plus ritonavir in HIV infection: pharmacology, efficacy and tolerability profile.
    Arvieux C; Tribut O
    Drugs; 2005; 65(5):633-59. PubMed ID: 15748098
    [TBL] [Abstract][Full Text] [Related]  

  • 38. HIV protease inhibitors elicit volume-sensitive Cl- current in cardiac myocytes via mitochondrial ROS.
    Deng W; Baki L; Yin J; Zhou H; Baumgarten CM
    J Mol Cell Cardiol; 2010 Nov; 49(5):746-52. PubMed ID: 20736017
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Atazanavir/ritonavir versus lopinavir/ritonavir: equivalent or different efficacy profiles?
    Hill A
    AIDS; 2005 Nov; 19(17):2054-5. PubMed ID: 16260922
    [No Abstract]   [Full Text] [Related]  

  • 40. Effects of ritonavir and amprenavir on insulin sensitivity in healthy volunteers.
    Lee GA; Rao M; Mulligan K; Lo JC; Aweeka F; Schwarz JM; Schambelan M; Grunfeld C
    AIDS; 2007 Oct; 21(16):2183-90. PubMed ID: 18090045
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.